Book Chapters, Reviews & Patents

Book Chapters, Reviews

  • Hanske, A.; Nazaré, M.; Grether, U. Chemical Probes for Investigating the Endocannabinoid System. Curr. Top. Behav. Neurosci. 2025. 10.1007/7854_2024_563
     
  • Aebi, J.; Atz, K.; Ametamey, S. M.; Benz, J.; Blaising, J.; Butini, S.; Campiani, G.; Carreira, E. M.; Collin, L.; de Lago, E.; Gazzi, T.; Gertsch, J.; Gobbi, L.; Guba, W.; Fernández-Ruiz, J.; Fingerle, J.; Haider, A.; He, Y.; Heitman, L. H.; Honer, M.; Hunziker, D.; Kuhn, B.; Maccarrone, M.; Märki, H. P.; Martin, R. E.; Mohr, P.; Mu, L.; Nazaré, M.; Nippa, D. F.; Oddi, S.; O’Hara, F.; Pacher, P.; Romero, J.; Röver, S.; Rufer, A. C.; Schibli, R.; Schneider, G.; Stepan, A. F.; Sykes, D. A.; Ullmer, C.; van der Stelt, M.; Veprintsev, D. B.; Wittwer, M. B.; Grether, U. Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche’s Endocannabinoid System Projects. Chimia 2024, 78, 499-512.
     
  • Kosar, M.; Mach, L.; Carreira, E. M.; Nazaré, M.; Pacher, P.; Grether, U., Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present), Expert Opinion on Therapeutic Patents, 2024, 34, 665–700. https://doi.org/10.1080/13543776.2024.2368745
     
  • Cirillo, D.; Diceglie, M.; Nazaré, M., Isoform-selective targeting of PI3K: time to consider new opportunities? Trends Pharmacol Sci., 2023, 44(9), 601-621.
    doi.org/10.1016/j.tips.2023.06.002
     
  • Guberman, M.; Kosar, M.; Omran, A.; Carreira, E. M.; Nazaré, M., Reverse-Design toward Optimized Labeled Chemical Probes – Examples from the Endocannabinoid System. Chimia, 2022, 76(5), 425. doi.org/10.2533/chimia.2022.425
     
  • Brennecke, B.; Gazzi, T.; Atz, K.; Fingerle, J.; Kuner, P.; Schindler, T.; Weck, G. d.; Nazaré, M.; Grether, U., Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. Pharmaceutical Patent Analyst 2021, 10, 111-163. doi.org/10.4155/ppa-2021-0002
     
  • Sykes, D. A.; Borrega-Roman, L.; Harwood, C. R.; Hoare, B.; Lochray, J. M.; Gazzi, T.; Briddon, S. J.; Nazaré, M.; Grether, U.; Hill, S. J.; Charlton, S. J.; Veprintsev, D. B., Kinetic Profiling of Ligands and Fragments Binding to GPCRs by TR-FRET. Springer Berlin Heidelberg: Berlin, Heidelberg, pp 1-32. doi.org/10.1007/7355_2021_120
     
  • Waiczies, Sonia; Prinz, Christian; Starke, Ludger; Millward, Jason M.; Delgado, Paula Ramos; Rosenberg, Jens et al. (2021): Functional Imaging Using Fluorine (19F) MR Methods: Basic Concepts. In: Methods in molecular biology (Clifton, N.J.) 2216, S. 279–299. doi.org/10.1007/978-1-0716-0978-1_17
     
  • Guba, Wolfgang; Nazaré, Marc; Grether, Uwe (2021): Chapter 4. Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor. In: Mauro Maccarrone (Hg.): New tools to interrogate endocannabinoid signalling. From natural compounds to synthetic drugs. Cambridge, England: Royal Society of Chemistry (RSC drug discovery series, 76), S. 89–167. doi.org/10.1039/9781839160752-00089
     
  • Fälker, K.; Nazaré; M., Wonerow, P.; Kozian, D. H.; Targeting Platelet G Protein-Coupled Receptors for Antithrombotic Therapy. Drug Dev. Res. 2013, 74, 440–449. doi.org/10.1002/ddr.21101
  • Matter, Hans; Nazaré, Marc; Güssregen, Stefan (2012): Halogen…π Interactions as Important Contributors to Binding Affinity in Medicinal Chemistry. In: Edward R. T. Tiekink und Júlio Zukerman-Schpector (Hg.): The importance of Pi-interactions in crystal engineering. Frontiers in crystal engineering. Hoboken, NJ: Wiley, S. 187–232. doi.org/10.1002/9781119945888.ch8

Patents

  • Benz, J.; Giroud, M.; Grether, U.; Guberman, M.; He, Y.; Mu, L.; Hentsch, A.; Kuhn, B.; Martin, R.; Nazare, M.; O'Hara, F. ; Paul, J. ; Puellmann, B.; Ritter, M., 2-azaspiro[3.3]heptanecarboxylates as probes for MAGL. WO2025082936.
  • Wasinska-Kalwa, M.; Omran, A.; Mostinski, Y.; Mach, L.; Nazare, M.; Grether, U.; Guba, W.; Novel irreversible fluorescent probes for cannabinoid receptor 1. WO2025104044.
  • Wasinska-Kalwa, M.; Omran, A.; Mostinski, Y.; Mach, L.; Nazare, M.; Grether, U.; Guba, W. Novel reversible fluorescent probes for CB2. WO2025104141.
  • Cirillo, D.; Lo, W.-T.; Haucke, V.; Nazare, M. Thiazolo Tetrahydrochinoline Compounds As Class Ii Phosphoinositide 3-Kinase Inhibitors. WO2025003330.
  • Scheidereit, C.; Mucka, P.; Willenbrock, M.; Bosco, B.; Lindemann, P.; Radetzki, S.; Von Kries, J. P.; Nazare, M. Pyrazolo-Quinolines As Selective Inhibitors Of Genotoxic Stress-Induced IKK/NF- KB Pathways For Cancer Therapy. WO2024240877.
  • Benz, J.; Giroud, M.; Grether, U.; Guberman, M.; Hentsch, A.; Kuhn, B.; Martin, R. E.; Nazare, M.; O'Hara, F.; Paul, J.; Puellmann, B.; Ritter, M. Fluorescent probes for MAGL.
    WO2024061853
  • Benz, J.; Giroud, M.; Grether, U.; Guberman, M.; Hentsch, A.; Kuhn, B.; Martin, R. E.; Nazare, M.; O'Hara, F.; Paul, J.; Puellmann, B.; Ritter, M. Fluorescent probes for MAGL.
    WO2023247666
  • Benz, J.; Gazzi, T.; Gobbi, L.; Grether, U.; Hornsperger, B.; Kroll, C.; Kuhn, B.; Mostinski, Y.; Nazaré, M.; O'Hara, F.; Richter, H. Fluorescent probes for monoacylglycerol lipase (MAGL). WO2021058443
     
  • Lo, W.-T.; Belabed, H.; Haucke, V.; Nazare, M.; Kuecuekdisli, M. Preparation of fused pyrimidinones as class II phosphoinositide 3-kinase inhibitors useful in treatment of diseases. WO2019234237
     
  • Krauss, S.; Nazare, M.; Anumala, U. R.; Lehtio, L.; Waaler, J.; Wegert, A.; Leenders, R. G. G. 1,2,4-Triazole derivatives as tankyrase inhibitors and their preparation. WO2019243822
     
  • Krauss, S.; Nazare, M.; Anumala, U. R.; Lehtio, L.; Waaler, J.; Holsworth, D.; Wegert, A.; Leenders, R. G. G. Preparation of triazole derivatives as tankyrase inhibitors useful in treatment and prevention of diseases. WO 2018118868
     
  • Scheidereit, C.; Willenbrock, M.; Lindemann, P.; Radetzki, S.; Von Kries, J. P.; Nazare, M.; Preparation of polycyclic nitrogen heterocycles as selective inhibitors of genotoxic stress-induced IKK/NF-kB pathways for the treatment of diseases. WO 2018087389
     
  • Bader, M.; Specker, E.; Matthes, S.; Schuetz, A.; Mallow, K., Grohmann, M. Nazare, M. Preparation of xanthine derivatives as tryptophan hydroxylase inhibitors for the treatment of serotonin-related disorders. WO 2018019917
     
  • Krause, G.; Hoyer, I.; Specker, E.; Furkert, J.; Marcinkowski, P.; Von Kries, J.-P.; Neuenschwander, M.; Nazare, M. Synthesis of antagonists of the thyroid-​stimulating hormone receptor (TSHR). WO 2017186793
     
  • Bader, M.; Specker, E.; Matthes, S.; Schuetz, A.; Mallow, K.; Grohmann, M.; Nazaré, M. Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same. WO 2016135199
     
  • Hu, H.-Y; Nazare, M.; Han Lim, N.; Ding-Pfennigdorff, D.; Plettenburg, O.; Ritzeler, O; Juretschke, H.-P.; Saas, J.; Bartnik, E.; Florian, P.; Wendt, U.; Schultz, C.; Nagase, H. DOTAM derivatives for therapeutic use. WO 2015075699
     
  • Nazaré, M.; Halland, N.; Schmidt, F.; Kleemann, H.-W.; Weiss, T.; Saas, J.; Struebing, C.; N-(4-(Azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals. WO 2014140065
     
  • Petry, S; Nazaré, M.; Schmidt, T.; Matter, H.; Fluorescence-labelled fatty acids binding to fatty acid-binding compd. to elicit FRET (Foerster resonance energy transfer) and uses thereof. WO 2014037394
     
  • Nazaré, M.; Kozian, D.; Bossart, M., Czechtizky, W., Evers, A. Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists. WO 2013171318.
     
  • Nazaré, M.; Kozian, D.; Evers, A.; Czechtizky, W. Pyrazole derivatives and their use as LPAR5 antagonists. WO 2013171317.
     
  • Nazaré, M.; Kozian, D.; Evers, A.; Czechtizky, W. Pyridine derivatives and their use as LPAR5 antagonists. WO 2013171316.
     
  • Nazaré, M.; Halland, N.; Schmidt, F.; Weiß, T.; Dietz, U.; Hofmeister, A. N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl] sulfonamide derivatives as kinase inhibitors. WO 2013041119.
     
  • Nazaré, M.; Zech, G.; Just, M.; Weiss, T.; Hessler, G.; Kohlmann, M. Preparation of heterocyclic pyrazole-carboxamides as P2Y12 antagonists for treating cardiovascular diseases and other disorders. WO 2009080226.
     
  • Nazaré, M.; Zech, G.; Goerlitzer, J.; Just, M.; Weiss, T.; Hessler, G.; Czechtizky, W.; Ruf, S. Preparation of pyrazole-carboxamide derivatives as P2Y12 antagonists for treating cardiovascular disorders. WO 2009080227.
     
  • R'Kyek, O.; Nazaré, M.; Lindenschmidt, A.; Urmann, M.; Halland, N.; Alonso, J. A process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates. WO 2009003589.
     
  • R'Kyek, O.; Nazaré, M.; Lindenschmidt, A.; Alonso, J.; Urmann, M.; Halland, N.; A process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates. WO 2009003590.
     
  • Alonso, J.; Lindenschmidt, A.; Nazaré, M.; Urmann, M.; Halland, N.; R'Kyek, O. A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles. WO 2009000413.
     
  • Alonso, J.; Lindenschmidt, A.; Nazaré, M.; R'Kyek, O.; Urmann, M.; Halland, N. A regioselective metal catalyzed synthesis of annulated benzimidazoles and azabenzimidazoles.; WO 2009000412.
     
  • Halland, N.; Nazaré, M.; Lindenschmidt, A.; Alonso, J.; R'Kyek, O.; Urmann, M. A transition metal catalyzed synthesis of 2H-indazoles. WO 2009000411.
     
  • Nazaré, M.; Zech, G.; Just, M.; Weiss, T.; Hessler, G.; Czech, J. Quinoline-carboxamide derivatives as P2Y12 antagonists and their preparation, pharmaceutical compositions and use in the treatment of cardiovascular diseases. WO 2008128647.
     
  • Halland, N.; Nazaré, M.; Lindenschmidt, A.; Rkyek, O.; Urmann, M.; Alonso, J. A transition metal catalyzed synthesis of N-aminoindoles. WO 2008125207.
     
  • Alonso, J.; Lindenschmidt, A.; Nazaré, M.; Halland, N.; Rkyek, O.; Urmann, M. A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles from halonitroarenes and amides. WO 2008009348.
     
  • Wagner, M.; Urmann, M.; Wehner, V.; Lorenz, M.; Bauer, A.; Nazaré, M.; Matter, H.; Preparation of heteroarylcarboxylic acid sulfamoylalkyl amides as factor Xa inhibitors. WO 2006122661.
     
  • Urmann, M.; Nazaré, M.; Matter, H.; Wehner, V.; Bauer, A.; Wagner, M., Beta-aminoacid-derivatives as factor Xa inhibitors. WO 2005095440.
     
  • Bauer, A.; Wagner, M.; Nazaré, M.; Wehner, V.; Urmann, M.; Matter, H. Pyrrole-derivatives as factor Xa inhibitors. WO 2005085239.
     
  • Nazaré, M.; Laux, V.; Bauer, A.; Wagner, M. Triazole-derivatives as factor Xa inhibitors. WO 2004101555.
     
  • Nazaré, M.; Wehner, V.; Laux, V.; Urmann, M.; Bauer, A.; Matter, H. Indazole-derivatives as factor Xa inhibitors.  WO 2004101556.
     
  • Nazaré, M.; Wehner, V.; Will, D. W.; Ritter, K.; Urmann, M.; Matter, H. Azaindole-derivatives as factor Xa inhibitors.WO 2004101563.
     
  • Nazaré, M.; Wagner, M.; Wehner, V.; Matter, H.; Urmann, M.; Ritter, K.  Benzimidazole-derivatives as factor Xa inhibitors. WO 2004101553.
     
  • Nazaré, M.; Wehner, V.; Ritter, K.; Laux, V.  New Indole-derivatives as factor Xa inhibitors WO 2004101554.
     
  • Nazaré, M.; Bauer, A.; Wehner, V.; Will, D. W.; H. Matter, H.; Wagner, M.; Schreuder, H.  Imidazole-derivatives as factor Xa inhibitors. WO 200405636.
     
  • Nazaré, M.; Wehner, V.; Will, D. W.; Matter, H.  Pyrazole-derivatives as factor Xa inhibitors. WO2004056815.
     
  • Nazaré, M.; Essrich, M.; Will, D. W.; Matter, H.; Ritter, K.; Wehner, V.  Preparation of indole-2-carboxamides as factor Xa inhibitors. WO 2003044014.
     
  • Nazaré, M.; Will, D. W.; Peyman, A.; Matter, H.; Zoller, G.; Gerlach, U.  Oxybenzamides derivatives as factor Xa inhibitors. WO 2002051831.
     
  • Peyman, A.; Will, D. W.; Gerlach, U.; Nazaré, M.; Zoller, G.; Nestler, H.-P.; Matter, H.; Al-Obeidi, F.  Preparation of guanidines and amidines as Factor Xa and/or VIIa inhibitors. WO 2002046159.